Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EXOZ, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
EXOZ holds $5.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.6M/quarter from operations, an estimated runway of 10.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 62 · High
Accordingly, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern one year from the date that these unaudited condensed consolidated financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EXOZ files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Anthony Digiandomenico Director, 10% owner · +10,000 options |
Insider | 3,808,476 | 40.34% | 2026-10-01 |
| Christopher A Marlett Director, 10% owner · +10,000 options Includes shares also reported by Anthony Digiandomenico, counted once |
Insider | 3,808,476 | 40.34% | 2026-10-01 |
| MDB Capital Holdings, LLC 10% owner Includes shares also reported by Anthony Digiandomenico, counted once |
Insider | 3,808,476 | 40.34% | 2024-11-08 |
| Tyler Paz Korman Chief Scientific Officer · +79,104 options |
Insider | 729,123 | 7.72% | 2026-08-19 |
| Paul Hideo Opgenorth Vice President, Development |
Insider | 645,149 | 6.83% | 2026-04-01 |
| James Ulrich Bowie Director · +10,000 options |
Insider | 577,910 | 6.12% | 2026-10-01 |
| Mohammad Hayat President & Chairman of Board, Director |
Insider | 155,818 | 1.65% | 2024-11-08 |
| Edgardo Javier Rayo Director · +25,000 options |
Insider | 77,909 | 0.83% | 2026-10-01 |
| Damien Alan Perriman Chief Commercial Officer · +185,662 options |
Insider | 28,692 | 0.30% | 2026-10-09 |
| Michael Heltzen Chief Executive Officer · +235,817 options |
Insider | 13,853 | 0.15% | 2026-08-19 |
| Fouad Nawaz Vice President- Finance · +45,000 options |
Insider | 9,488 | 0.10% | 2026-09-14 |
Share count 9,439,915 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EXOZ and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →